Ali Zaza
Surgery · Oklahoma City, OKNPI 1376522789
Payments from drug & device makers
Across 45 payments — averaging $122.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$3K
- Medtronic$710
- Davol Inc.$337
- Relievant Medsystems, Inc.$151
- Stratus Medical, LLC$150
- AbbVie$146
- plus $546 from 6 others
What the payments were for
- Travel & lodging$2,66748%
- Food & beverage$2,83552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 23 | $3,460 |
| Medtronic(2 entities) | 5 | $710 |
| Davol Inc. | 6 | $337 |
| Relievant Medsystems, Inc. | 1 | $151 |
| Stratus Medical, LLC | 1 | $150 |
| AbbVie | 1 | $146 |
| Boston Scientific | 1 | $141 |
| SPR Therapeutics, Inc | 1 | $132 |
| Endogastric Solutions, Inc | 1 | $103 |
| TELA Bio, Inc. | 3 | $98 |
| AstraZeneca | 1 | $54 |
| Fujifilm Healthcare Americas Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE BIO-A Tissue Reinforcement$2,750
- Intracept$745
- INTELLIS ADAPTIVESTIM$273
- SYNECOR Biomaterial$174
- Signia$162
- Nimbus$150
- PHASIX$148
- STRATTICE$146
- AbsorbaTack$143
- INTELLIS$132
- SPRINT PNS System$132
- ESOPHYX$103
How this compares
$5,502 in reported general payments places this provider in the 75th percentile of 290 surgery providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $13,656 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,575 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,413 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $581 |
| Levothyroxine Sodium | 33 | $280 |
| Simvastatin | 11 | $173 |
| Lisinopril | 13 | $123 |
| Metformin Hcl | 11 | $65 |
| Atorvastatin Calcium | 19 | $43 |
Paid to pharmacies, not to this prescriber.
Other surgery in Oklahoma City
- Alisa CrossOklahoma City$262K
- Christopher CareyOklahoma City$39K
- Alexander RainesOklahoma City$36K
- Joshua GiermanOklahoma City$19K
- Christopher HenryOklahoma City$16K
- Brian HerrittOklahoma City$12K
- Carson AgeeOklahoma City$11K
- Marcia MooreOklahoma City$11K
- Joseph BuendiaOklahoma City$11K
- Laura FischerOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.